World-Renowned Doctors.
Life-Changing Discoveries.
Revolutionary Care.

Our Hematology (Blood Disorders), Thrombosis Prevention and Treatment Program and our Sickle Cell Center are also among the largest programs of their kind in the nation. We are a myelodysplastic syndrome (MDS) Center of Excellence and one of the few centers in the nation with an active phase 1 clinical trials program using cellular therapies to treat patients with solid tumors. We are a referral site for the most complex and rare cases, with some of the highest stem cell transplant survival rates in the U.S. We are a global leader, renowned for cutting-edge research and dedication to delivering the most compassionate and highest-quality care for all individuals. Home to world-renowned hematologists, medical oncologists and PhD-level scientists with a track record of pioneering innovations that have redefined the field, we are committed to advancing the prevention, diagnosis and treatment of the full range of hematology conditions (blood disorders), blood cancers and solid tumors. 

Our multidisciplinary team is renowned for developing novel immunotherapies, including CAR T-cell therapies, immune checkpoint inhibitors, personalized cancer vaccines, antibody–drug conjugates, and monoclonal and bispecific antibodies for hard-to-treat solid tumors, blood cell cancers and other diseases. We are one of the few gene-therapy-certified treatment centers for sickle cell disease in the U.S. and one of the nation’s premier destinations for clotting disorders.

Fully integrated with our National Cancer Institute (NCI)-designated Comprehensive Cancer Center, our medical oncologists collaborate closely with pathologists and radiation and surgical oncologists on multidisciplinary tumor boards to examine each patient’s case and treatment options and guide a comprehensive, personalized plan. By offering access to some of the most innovative treatments available today, our clinical trials program enables us to identify and enroll patients in more than 300 cutting-edge trials.

We have been leading the way with groundbreaking research for more than a century and continue to advance the field with new scientific discoveries and innovations. From life-changing discoveries that led to the discovery of anti‐P‐selectin monoclonal antibodies for vaso‐occlusion in sickle cell disease (SCD) to leading the largest adjuvant breast cancer treatment trial ever done, our researchers are pushing the boundaries of modern science. We were one of the first contributors to epigenetics, the study of how genetic factors affect heritable defects like SCD, and we are pioneers in hematopoietic stem cell research. Our Sickle Cell Research Laboratory was the first of its kind in the nation, and the Montefiore Einstein Comprehensive Cancer Center was one of the first in the nation to be designated by the NCI and is one of only 57 comprehensive cancer centers in the U.S. Through more than 300 hematology and oncology clinical trials, our patients can access emerging technologies and innovative treatments that may be unavailable to the general public.    

As pioneers in bone marrow transplantation and cellular therapies, our Foundation for the Accreditation of Cellular Therapy (FACT)-accredited Stem Cell and Cellular Therapy Program provides a full array of transplant options, including autologous, matched-related, matched-unrelated and haploidentical (half-matched) transplants. Our program performs hundreds of transplants and CAR T-cell therapies annually. We are one of only a few Centers of Excellence for CAR T-cell therapy in the U.S. and were instrumental in paving the way for Food and Drug Administration (FDA) approval of the first Cluster of Differentiation 19-targeted CAR T-cell therapy for B-cell hematologic malignancies. We are one of the few centers in the nation with an active phase 1 clinical trial program using cellular therapies to treat patients with solid tumors, and we were one of the first to pioneer the use of CAR T-cell therapy for the treatment of AIDS-related lymphoma. Our stem cell transplant team is also at the forefront of hematopoietic stem cell transplantation as a potential cure for a variety of classical hematologic conditions and other nonmalignant diseases.

Advancing health, scientific discovery and innovation through groundbreaking blood disorders (hematologic conditions) and cancer research.

Learn about our state-of-the-art screenings offered at the Montefiore Einstein Comprehensive Cancer Center, designed to detect cancer at the earliest, most treatable stages.

Our multidisciplinary team of world-renowned hematologists and medical oncologists specializes in the prevention, diagnosis and management of the full spectrum of hematologic conditions, blood cancers and solid tumors, delivering comprehensive, compassionate and personalized care. We are committed to eliminating cancer, optimizing outcomes and improving the quality of life for all patients and their families.